tesmilifene has been researched along with Neoplasm Metastasis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dancey, J; Dent, S; Garin, A; Gelmon, K; Gorbunova, V; Jassem, J; Lebwohl, D; MacNeil, M; Marlin, S; Pearce, L; Pienkowski, T; Pluzanska, A; Pritchard, K; Reyno, L; Seymour, L; Tu, D; Voi, M; Walley, B | 1 |
Dancey, J; Liu, J; Pater, J; Pritchard, KI; Reyno, L; Seymour, LK; Tu, D | 1 |
2 trial(s) available for tesmilifene and Neoplasm Metastasis
Article | Year |
---|---|
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Phenyl Ethers; Platelet Aggregation Inhibitors; Quality of Life; Treatment Outcome | 2004 |
Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Doxorubicin; Fatigue; Female; Health Status; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neurotoxicity Syndromes; Patient Compliance; Phenyl Ethers; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2006 |